1. Home
  2. CINGW vs KTOS Comparison

CINGW vs KTOS Comparison

Compare CINGW & KTOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • KTOS
  • Stock Information
  • Founded
  • CINGW N/A
  • KTOS 1994
  • Country
  • CINGW United States
  • KTOS United States
  • Employees
  • CINGW 13
  • KTOS N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • KTOS Military/Government/Technical
  • Sector
  • CINGW Health Care
  • KTOS Industrials
  • Exchange
  • CINGW Nasdaq
  • KTOS Nasdaq
  • Market Cap
  • CINGW N/A
  • KTOS N/A
  • IPO Year
  • CINGW 2021
  • KTOS 1999
  • Fundamental
  • Price
  • CINGW $0.05
  • KTOS $32.12
  • Analyst Decision
  • CINGW
  • KTOS Buy
  • Analyst Count
  • CINGW 0
  • KTOS 10
  • Target Price
  • CINGW N/A
  • KTOS $32.33
  • AVG Volume (30 Days)
  • CINGW N/A
  • KTOS 2.2M
  • Earning Date
  • CINGW N/A
  • KTOS 05-06-2025
  • Dividend Yield
  • CINGW N/A
  • KTOS N/A
  • EPS Growth
  • CINGW N/A
  • KTOS N/A
  • EPS
  • CINGW N/A
  • KTOS 0.11
  • Revenue
  • CINGW N/A
  • KTOS $1,136,300,000.00
  • Revenue This Year
  • CINGW N/A
  • KTOS $15.11
  • Revenue Next Year
  • CINGW N/A
  • KTOS $15.60
  • P/E Ratio
  • CINGW N/A
  • KTOS $291.79
  • Revenue Growth
  • CINGW N/A
  • KTOS 9.56
  • 52 Week Low
  • CINGW N/A
  • KTOS $17.05
  • 52 Week High
  • CINGW N/A
  • KTOS $35.66
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • KTOS 54.56
  • Support Level
  • CINGW N/A
  • KTOS $31.48
  • Resistance Level
  • CINGW N/A
  • KTOS $33.94
  • Average True Range (ATR)
  • CINGW 0.00
  • KTOS 1.88
  • MACD
  • CINGW 0.00
  • KTOS 0.11
  • Stochastic Oscillator
  • CINGW 0.00
  • KTOS 77.70

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: